FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308017635> ?p ?o ?g. }

• W4308017635 endingPage "1010" @default.
• W4308017635 startingPage "992" @default.
• W4308017635 abstract "Improving the detection rates of prostate cancer (PCa) and avoiding unnecessary prostate biopsies in men with prostate-specific antigen (PSA) levels within the gray zone require urgent attention. In this context, rapid advances in MR technology in recent years may offer a promising possibility. A systematic review to evaluate the applications of magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in detecting PCa and clinically significant PCa (csPCa) in men with PSA levels within the gray zone. The study type is defined as systematic review. In July 2022, out of 229 studies identified by the database search and from other sources, 23 articles related to the selected topic of interest were included in this review. No field strength or sequence restrictions. The data including the study population, study characteristics, as well as basic MRI characteristics, from the final studies included in this review, were extracted independently by two reviewers. The major results of the original study were summarized and no additional statistical analysis was performed. Among the 23 studies included in this review, 17 focused on the applications of MRS and MRI for the prebiopsy diagnosis of PCa. Nine of these 17 articles used Prostate Imaging Reporting and Data System (PI-RADS) score to interpret MRI results, thereby confirming the practicality of the PI-RADS score in predicting PCa and csPCa. The remaining six articles evaluated the applications of MRI and MRS in guiding prostate biopsy. Although there was a variation in the biopsy modalities used in these studies, both MRI- and MRS-guided prostate biopsies were observed to improve the detection rates of PCa and csPCa in patients with PSA levels within the gray zone. MRS and MRI showed good performance in the detection of PCa and csPCa before biopsy. In addition, MRS- or MRI-guided prostate-targeted biopsies were able to improve the detection rates of PCa and csPCa. EVIDENCE LEVEL: 3 TECHNICAL EFFICACY: Stage 2." @default.
• W4308017635 created "2022-11-07" @default.
• W4308017635 creator A5022109674 @default.
• W4308017635 creator A5080491619 @default.
• W4308017635 creator A5083992043 @default.
• W4308017635 date "2022-11-03" @default.
• W4308017635 modified "2023-10-10" @default.
• W4308017635 title "Patients With “Gray Zone” PSA Levels: Application of Prostate MRI and MRS in the Diagnosis of Prostate Cancer" @default.
• W4308017635 cites W1514451204 @default.
• W4308017635 cites W1525323466 @default.
• W4308017635 cites W1827911007 @default.
• W4308017635 cites W1856991762 @default.
• W4308017635 cites W1997698962 @default.
• W4308017635 cites W2018807319 @default.
• W4308017635 cites W2095412905 @default.
• W4308017635 cites W2103315071 @default.
• W4308017635 cites W2107638293 @default.
• W4308017635 cites W2112271714 @default.
• W4308017635 cites W2122754822 @default.
• W4308017635 cites W2123369557 @default.
• W4308017635 cites W2156098321 @default.
• W4308017635 cites W2285962956 @default.
• W4308017635 cites W2335679869 @default.
• W4308017635 cites W2395925941 @default.
• W4308017635 cites W2407415728 @default.
• W4308017635 cites W2584759710 @default.
• W4308017635 cites W2616913649 @default.
• W4308017635 cites W2727380696 @default.
• W4308017635 cites W2752975759 @default.
• W4308017635 cites W2791410183 @default.
• W4308017635 cites W2793905111 @default.
• W4308017635 cites W2806817930 @default.
• W4308017635 cites W2808164498 @default.
• W4308017635 cites W2886606374 @default.
• W4308017635 cites W2892147080 @default.
• W4308017635 cites W2896768253 @default.
• W4308017635 cites W2900349954 @default.
• W4308017635 cites W2902304006 @default.
• W4308017635 cites W2907438225 @default.
• W4308017635 cites W2916635783 @default.
• W4308017635 cites W2922071185 @default.
• W4308017635 cites W2955292737 @default.
• W4308017635 cites W2955907881 @default.
• W4308017635 cites W2967716184 @default.
• W4308017635 cites W2991792334 @default.
• W4308017635 cites W2993640809 @default.
• W4308017635 cites W2994894232 @default.
• W4308017635 cites W2995626084 @default.
• W4308017635 cites W3005710123 @default.
• W4308017635 cites W3012056506 @default.
• W4308017635 cites W3014844876 @default.
• W4308017635 cites W3015722134 @default.
• W4308017635 cites W3021941567 @default.
• W4308017635 cites W3039899351 @default.
• W4308017635 cites W3044955059 @default.
• W4308017635 cites W3127784655 @default.
• W4308017635 cites W3128646645 @default.
• W4308017635 cites W3136365458 @default.
• W4308017635 cites W3175592081 @default.
• W4308017635 cites W3201057963 @default.
• W4308017635 cites W3206994608 @default.
• W4308017635 cites W3212174834 @default.
• W4308017635 cites W3214479153 @default.
• W4308017635 cites W3217233110 @default.
• W4308017635 doi "https://doi.org/10.1002/jmri.28505" @default.
• W4308017635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36326563" @default.
• W4308017635 hasPublicationYear "2022" @default.
• W4308017635 type Work @default.
• W4308017635 citedByCount "3" @default.
• W4308017635 countsByYear W43080176352023 @default.
• W4308017635 crossrefType "journal-article" @default.
• W4308017635 hasAuthorship W4308017635A5022109674 @default.
• W4308017635 hasAuthorship W4308017635A5080491619 @default.
• W4308017635 hasAuthorship W4308017635A5083992043 @default.
• W4308017635 hasConcept C121608353 @default.
• W4308017635 hasConcept C126322002 @default.
• W4308017635 hasConcept C126838900 @default.
• W4308017635 hasConcept C143409427 @default.
• W4308017635 hasConcept C151730666 @default.
• W4308017635 hasConcept C2775934546 @default.
• W4308017635 hasConcept C2776235491 @default.
• W4308017635 hasConcept C2779343474 @default.
• W4308017635 hasConcept C2780192828 @default.
• W4308017635 hasConcept C2781217009 @default.
• W4308017635 hasConcept C2781406297 @default.
• W4308017635 hasConcept C71924100 @default.
• W4308017635 hasConcept C86803240 @default.
• W4308017635 hasConceptScore W4308017635C121608353 @default.
• W4308017635 hasConceptScore W4308017635C126322002 @default.
• W4308017635 hasConceptScore W4308017635C126838900 @default.
• W4308017635 hasConceptScore W4308017635C143409427 @default.
• W4308017635 hasConceptScore W4308017635C151730666 @default.
• W4308017635 hasConceptScore W4308017635C2775934546 @default.
• W4308017635 hasConceptScore W4308017635C2776235491 @default.
• W4308017635 hasConceptScore W4308017635C2779343474 @default.
• W4308017635 hasConceptScore W4308017635C2780192828 @default.
• W4308017635 hasConceptScore W4308017635C2781217009 @default.
• W4308017635 hasConceptScore W4308017635C2781406297 @default.

• next